Hims & Hers Expands in Europe with Zava Acquisition and New Obesity Drugs

Hims & Hers is planning to offer replica obesity medications in the UK and Europe, following its acquisition of European rival Zava, aiming to provide more affordable and personalized weight loss treatments. The company sees a significant opportunity in the obesity market and plans to expand its offerings, including personalized compounded medications, amid ongoing demand for such treatments. This move aligns with the company's strategy to diversify its portfolio and capitalize on the growing telemedicine and obesity treatment markets.